Cloning and Mutagenesis Market
Upcoming research reports. Delivery timeline: 4 weeks
Cloning and mutagenesis are molecular biology techniques used to manipulate DNA for research, therapeutic, or industrial applications. The cloning and mutagenesis market is mainly driven by factors such as growing advancements in genomic technologies, increasing focus on personalized approach to therapeutics and increasing prevalence of genetic diseases. However, complexity of the techniques employed for cloning and mutagenesis along with few ethical concers are expected to pose challenges to the market growth.
Cloning and mutagenesis market- global forecast to 2030
Global Cloning and Mutagenesis Market Dynamics
DRIVER: Growing advancements in genomic technologies
Advancements in genomic technologies have transformed the field of cloning and mutagenesis, making it a powerful driver for the market. Modern genomic tools have significantly improved the precision and efficiency of cloning and mutagenesis processes. Technologies like DNA printing enable the creation of synthetic genes without requiring a template. This reduces the dependency on natural DNA samples and accelerates cloning workflows. Moreover, Genomic advancements have brought automation and scalability to cloning and mutagenesis. NGS allows rapid verification of cloning and mutagenesis results, ensuring higher accuracy in applications like gene therapy and diagnostics.
RESTRAINT: Complexity of techniques
The complexity of techniques in cloning and mutagenesis acts as a significant restraint to market growth, particularly for smaller organizations or less-experienced users. Many cloning and mutagenesis techniques are intricate and require advanced skills and training. Processes like PCR, restriction digestion, ligation, and transformation demand a deep understanding of molecular biology and biochemistry in case of cloning. Even small errors, such as incorrect primer design or poor reaction conditions, can lead to failed experiments. Mutagenesis requires precision in designing primers and understanding the gene of interest. Achieving site-specific changes without introducing off-target effects can be technically challenging.
Recent Developments:
In May 2022, Qiagen acquired BLIRT, QIAGEN N.V. announced the acquisition of a 96% majority ownership stake in BLIRT S.A., a Gdansk, Poland-based manufacturer of recombinant enzymes for the life science industry. This strategic move aims to enhance QIAGEN's capabilities in enzyme development and production, thereby strengthening its sample technologies and expanding its global presence. The integration of BLIRT's specialized enzyme portfolio is expected to create additional growth opportunities for QIAGEN's existing offerings.
In February 2022, Tamara Bio, Inc., a central hub for cell and general processing in Japan, announced the expansion of its production facilities. The newly established laboratory will focus on manufacturing products such as cancer immunotherapy drugs, gene therapies, DNA and RNA vaccines, and leveraging cloning and mutagenesis techniques for regenerative medicine applications.
Cloning and mutagenesis are molecular biology techniques used to manipulate DNA for research, therapeutic, or industrial applications. The cloning and mutagenesis market is mainly driven by factors such as growing advancements in genomic technologies, increasing focus on personalized approach to therapeutics and increasing prevalence of genetic diseases. However, complexity of the techniques employed for cloning and mutagenesis along with few ethical concers are expected to pose challenges to the market growth.
Cloning and mutagenesis market- global forecast to 2030
Global Cloning and Mutagenesis Market Dynamics
DRIVER: Growing advancements in genomic technologies
Advancements in genomic technologies have transformed the field of cloning and mutagenesis, making it a powerful driver for the market. Modern genomic tools have significantly improved the precision and efficiency of cloning and mutagenesis processes. Technologies like DNA printing enable the creation of synthetic genes without requiring a template. This reduces the dependency on natural DNA samples and accelerates cloning workflows. Moreover, Genomic advancements have brought automation and scalability to cloning and mutagenesis. NGS allows rapid verification of cloning and mutagenesis results, ensuring higher accuracy in applications like gene therapy and diagnostics.
RESTRAINT: Complexity of techniques
The complexity of techniques in cloning and mutagenesis acts as a significant restraint to market growth, particularly for smaller organizations or less-experienced users. Many cloning and mutagenesis techniques are intricate and require advanced skills and training. Processes like PCR, restriction digestion, ligation, and transformation demand a deep understanding of molecular biology and biochemistry in case of cloning. Even small errors, such as incorrect primer design or poor reaction conditions, can lead to failed experiments. Mutagenesis requires precision in designing primers and understanding the gene of interest. Achieving site-specific changes without introducing off-target effects can be technically challenging.
Recent Developments:
In May 2022, Qiagen acquired BLIRT, QIAGEN N.V. announced the acquisition of a 96% majority ownership stake in BLIRT S.A., a Gdansk, Poland-based manufacturer of recombinant enzymes for the life science industry. This strategic move aims to enhance QIAGEN's capabilities in enzyme development and production, thereby strengthening its sample technologies and expanding its global presence. The integration of BLIRT's specialized enzyme portfolio is expected to create additional growth opportunities for QIAGEN's existing offerings.
In February 2022, Tamara Bio, Inc., a central hub for cell and general processing in Japan, announced the expansion of its production facilities. The newly established laboratory will focus on manufacturing products such as cancer immunotherapy drugs, gene therapies, DNA and RNA vaccines, and leveraging cloning and mutagenesis techniques for regenerative medicine applications.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT METHODOLOGY (TOP DOWN APPROACH)
2.3 MARKET GROWTH FORECAST
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 POLYMERASE CHAIN REACTION (PCR)
5.7.1.2 NEXT-GENERATION SEQUENCING (NGS)
5.7.2 COMPLIMENTARY TECHNOLOGIES
5.7.2.1 CRISPR/CAS9 GENOME EDITING
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.9.2 REGULATORY FRAMEWORK
5.10 PRICING ANALYSIS
5.10.1 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY KEY PLAYER, 2023
5.10.2 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY REGION, 2023
5.11 KEY CONFERENCES AND EVENTS IN 2025-26
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.12.2 BUYING CRITERIA FOR END USERS
5.13 IMPACT OF AI/GENERATIVE AI ON CLONING & MUTAGENESIS MARKET
5.14 INVESTMENT AND FUNDING ACTIVITIES
6 CLONING & MUTAGENESIS MARKET, BY OFFERINGS
6.1 INTRODUCTION
6.2 PRODUCT
6.2.1 CLONING KITS
6.2.2 MUTAGENESIS KITS
6.2.3 OTHER PRODUCTS
6.3 SERVICE
7 CLONING & MUTAGENESIS MARKET, BY TECHNIQUE
7.1 INTRODUCTION
7.2 TOPO PCR CLONING
7.3 BLUNT END CLONING
7.4 SEAMLESS CLONING
7.5 SITE-DIRECTED MUTAGENESIS
7.6 OTHER TECHNIQUES
8 CLONING & MUTAGENESIS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 RESEARCH
8.3 THERAPEUTIC
8.4 OTHER APPLICATIONS
9 CLONING & MUTAGENESIS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.3 CROs & CMOs
9.4 ACADEMIC & RESEARCH INSTITUTES
9.5 DIAGNOSTIC LABORATORIES
10 CLONING & MUTAGENESIS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.3 CANADA
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.3 UK
10.3.4 FRANCE
10.3.5 ITALY
10.3.6 SPAIN
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF APAC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.1 BRAZIL
10.5.2 MEXICO
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
10.6.1 GCC COUNTRIES
10.6.2 REST OF MIDDLE EAST
10.7 AFRICA
10.6.1 MACROECONOMIC OUTLOOK FOR AFRICA
Note: This section will provide market sizes & forecast by phase, service type, therapy area, modality, delivery model, study design, and end user for each region and country.
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
11.3 REVENUE SHARE ANALYSIS, 2021-2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 CLONING & MUTAGENESIS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER,2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPANY FOOTPRINT, KEY PLAYERS,2023
11.6.1 COMPANY FOOTPRINT
11.6.2 REGIONAL FOOTPRINT
11.6.3 PRODUCTS FOOTPRINT
11.6.4 TECHNIQUE FOOTPRINT
11.6.5 APPLICATION FOOTPRINT
11.7 COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023
11.7.1 PROGRESSIVE COMPANIES
11.7.2 RESPONSIVE COMPANIES
11.7.3 DYNAMIC COMPANIES
11.7.4 STARTING BLOCKS
11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
11.7.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
11.8 BRAND/ SERVICE COMPARATIVE ANALYSIS
11.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE CLONING & MUTAGENESIS MARKET
11.10 COMPETITIVE SCENARIO AND TRENDS
11.9.1 PRODUCT/SERVICE LAUNCHES
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC INC. (PPD, INC.)
12.1.2 AGILENT TECHNOLOGIES, INC.
12.1.3 CHARLES RIVER LABORATORIES
12.1.4 GENSCRIPT
12.1.5 NEW ENGLAND BIOLABS
12.1.6 MERCK KGAA
12.1.7 BIO-RAD LABORATORIES
12.1.8 DANAHER CORPORATION
12.1.9 TAKARA BIO
12.1.10 PROMEGA
12.1.11 TRANSGEN BIOTECH CO., LTD.
12.1.12 JENA BIOSCIENCE GMBH
12.1.13 ASSAY GENIE
Note: Above list is an indicative list of companies. Details on business overview, financial information, service portfolio, recent developments, and MarketsandMarkets view will be provided for ~25 companies. These details might not be captured in the case of unlisted companies. The list of players provided is tentative and subject to change during the research.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
Note: The given segmentation is tentative and subject to change during the course of research.
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT METHODOLOGY (TOP DOWN APPROACH)
2.3 MARKET GROWTH FORECAST
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 POLYMERASE CHAIN REACTION (PCR)
5.7.1.2 NEXT-GENERATION SEQUENCING (NGS)
5.7.2 COMPLIMENTARY TECHNOLOGIES
5.7.2.1 CRISPR/CAS9 GENOME EDITING
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.9.2 REGULATORY FRAMEWORK
5.10 PRICING ANALYSIS
5.10.1 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY KEY PLAYER, 2023
5.10.2 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY REGION, 2023
5.11 KEY CONFERENCES AND EVENTS IN 2025-26
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.12.2 BUYING CRITERIA FOR END USERS
5.13 IMPACT OF AI/GENERATIVE AI ON CLONING & MUTAGENESIS MARKET
5.14 INVESTMENT AND FUNDING ACTIVITIES
6 CLONING & MUTAGENESIS MARKET, BY OFFERINGS
6.1 INTRODUCTION
6.2 PRODUCT
6.2.1 CLONING KITS
6.2.2 MUTAGENESIS KITS
6.2.3 OTHER PRODUCTS
6.3 SERVICE
7 CLONING & MUTAGENESIS MARKET, BY TECHNIQUE
7.1 INTRODUCTION
7.2 TOPO PCR CLONING
7.3 BLUNT END CLONING
7.4 SEAMLESS CLONING
7.5 SITE-DIRECTED MUTAGENESIS
7.6 OTHER TECHNIQUES
8 CLONING & MUTAGENESIS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 RESEARCH
8.3 THERAPEUTIC
8.4 OTHER APPLICATIONS
9 CLONING & MUTAGENESIS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.3 CROs & CMOs
9.4 ACADEMIC & RESEARCH INSTITUTES
9.5 DIAGNOSTIC LABORATORIES
10 CLONING & MUTAGENESIS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.3 CANADA
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.3 UK
10.3.4 FRANCE
10.3.5 ITALY
10.3.6 SPAIN
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF APAC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.1 BRAZIL
10.5.2 MEXICO
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
10.6.1 GCC COUNTRIES
10.6.2 REST OF MIDDLE EAST
10.7 AFRICA
10.6.1 MACROECONOMIC OUTLOOK FOR AFRICA
Note: This section will provide market sizes & forecast by phase, service type, therapy area, modality, delivery model, study design, and end user for each region and country.
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
11.3 REVENUE SHARE ANALYSIS, 2021-2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 CLONING & MUTAGENESIS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER,2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPANY FOOTPRINT, KEY PLAYERS,2023
11.6.1 COMPANY FOOTPRINT
11.6.2 REGIONAL FOOTPRINT
11.6.3 PRODUCTS FOOTPRINT
11.6.4 TECHNIQUE FOOTPRINT
11.6.5 APPLICATION FOOTPRINT
11.7 COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023
11.7.1 PROGRESSIVE COMPANIES
11.7.2 RESPONSIVE COMPANIES
11.7.3 DYNAMIC COMPANIES
11.7.4 STARTING BLOCKS
11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
11.7.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
11.8 BRAND/ SERVICE COMPARATIVE ANALYSIS
11.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE CLONING & MUTAGENESIS MARKET
11.10 COMPETITIVE SCENARIO AND TRENDS
11.9.1 PRODUCT/SERVICE LAUNCHES
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC INC. (PPD, INC.)
12.1.2 AGILENT TECHNOLOGIES, INC.
12.1.3 CHARLES RIVER LABORATORIES
12.1.4 GENSCRIPT
12.1.5 NEW ENGLAND BIOLABS
12.1.6 MERCK KGAA
12.1.7 BIO-RAD LABORATORIES
12.1.8 DANAHER CORPORATION
12.1.9 TAKARA BIO
12.1.10 PROMEGA
12.1.11 TRANSGEN BIOTECH CO., LTD.
12.1.12 JENA BIOSCIENCE GMBH
12.1.13 ASSAY GENIE
Note: Above list is an indicative list of companies. Details on business overview, financial information, service portfolio, recent developments, and MarketsandMarkets view will be provided for ~25 companies. These details might not be captured in the case of unlisted companies. The list of players provided is tentative and subject to change during the research.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
Note: The given segmentation is tentative and subject to change during the course of research.
